gsk201304176k4.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2013
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


 
 
 Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
 
 
The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 17 April 2013 of an increase in their notional interests in Ordinary Shares at a price of 1565.50 pence per Ordinary Share following the notional re-investment of the dividend paid to shareholders on 11 April 2013.
 
 
 
 
Ordinary Shares
Mr R G Connor
49.224
Mr P Thomson
49.224
Dr P J T Vallance
593.601
Ms E Walmsley
850.250
Mr C Weber
261.988
Mrs V A Whyte
49.224
 
 
The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
17 April 2013
 
 

 

 

 

 
 

  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 17, 2013
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc